-
1.发明申请Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases 审中-公开人软骨调蛋白（tig2），生产和用于治疗或诊断骨病，软骨疾病，软骨疾病，肥胖症，炎性疾病和皮肤病公开(公告)号：US20060100145A1
公开(公告)日：2006-05-11
申请号：US10533300
申请日：2003-10-24
申请人： Wolfgang Meder , Martin Wendland , Harald John , Rudolf Richter , Markus Meyer , Wolf-Georg Forssmann
发明人： Wolfgang Meder , Martin Wendland , Harald John , Rudolf Richter , Markus Meyer , Wolf-Georg Forssmann
IPC分类号： A61K38/22 , C40B40/10 , C07K14/575
CPC分类号： C07K14/705 , C07K14/47 , C07K14/51
摘要： The invention relates to the polypeptide COM and its derivatives, and methods for its preparation and recovery in a pure or partially purified form from body fluids and tissues, and its use as a medicament.
摘要翻译： 本发明涉及多肽COM及其衍生物及其制备和从体液和组织中纯化或部分纯化形式的回收方法及其作为药物的用途。
-
公开(公告)号：US20080242609A1
公开(公告)日：2008-10-02
申请号：US11907623
申请日：2007-10-15
CPC分类号： C07K14/605 , A61K38/00 , A61K38/1709 , A61K45/06 , A61K2300/00
摘要： A composition containing at least two of the following active substances A, B, C, wherein:A=at least one hormone stimulating the production of cAMP;B=at least one substance inhibiting the degradation of a cyclic nucleotide;C=at least one hormone stimulating the production of cGMP.
摘要翻译： 含有至少两种以下活性物质A，B，C的组合物，其中：A =至少一种刺激cAMP产生的激素; B =抑制环状核苷酸降解的至少一种物质; C =至少一种刺激cGMP产生的激素。
-
公开(公告)号：US20140024585A1
公开(公告)日：2014-01-23
申请号：US13084040
申请日：2011-04-11
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , A61K38/1709 , A61K45/06 , A61K2300/00
摘要： A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.
摘要翻译： 含有至少两种以下活性物质A，B，C的组合物，其中：A =至少一种刺激cAMP产生的激素; B =抑制环状核苷酸降解的至少一种物质; C =至少一种刺激cGMP产生的激素。
-
4.发明授权Use of urodilatin for treating chronic kidney failure with residual kidney functions 有权使用尿路清蛋白治疗慢性肾功能衰竭与残留肾功能公开(公告)号：US06831064B1
公开(公告)日：2004-12-14
申请号：US10088498
申请日：2002-07-18
IPC分类号： A61K3800
CPC分类号： A61K38/2242
摘要： Use of urodilatin for treating chronic renal insufficiency by stimulating the residual renal function.
摘要翻译： 用尿激酶治疗慢性肾功能不全通过刺激残留的肾功能。
-
公开(公告)号：US5891904A
公开(公告)日：1999-04-06
申请号：US937590
申请日：1997-09-29
申请人： Christian Stief , Torsten Strohmeyer , Wolf-Georg Forssmann , Markus Meyer , Peter Schulz-Knappe , Akmal Taher
发明人： Christian Stief , Torsten Strohmeyer , Wolf-Georg Forssmann , Markus Meyer , Peter Schulz-Knappe , Akmal Taher
IPC分类号： A61K31/381 , A61K31/4015 , A61K31/4166 , A61K31/517 , A61K31/541 , A61K31/40
CPC分类号： A61K31/4166 , A61K31/381 , A61K31/4015 , A61K31/517 , A61K31/541
摘要： The invention relates to the use of inhibitors of phosphodiesterase IV for the modulation of the motility and peristalsis of the hollow organs of the urogenital and gastrointestinal tract.
摘要翻译： 本发明涉及磷酸二酯酶IV抑制剂用于调节泌尿生殖道和胃肠道中空器官的运动和蠕动的用途。
-
公开(公告)号：US07732406B2
公开(公告)日：2010-06-08
申请号：US11400696
申请日：2006-04-07
IPC分类号： A61K38/17
CPC分类号： A61K38/2242 , A61K47/26
摘要： The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
摘要翻译： 本发明涉及尿钠肽如尿d素用于治疗患有心力衰竭的患者，例如急性失代偿性心力衰竭。 优选地，将包含有效量的尿布菌素的组合物在至少24小时和至多120小时，优选至少48小时的持续时间内静脉内施用于患者。
-
公开(公告)号：US20050106678A1
公开(公告)日：2005-05-19
申请号：US10760557
申请日：2004-01-21
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07H21/04 , C07K1/18 , C07K1/20 , C07K1/30 , C07K14/52 , C12N15/19 , C12P21/02 , C12P21/08 , C12Q1/68
CPC分类号： C07K14/523 , A61K38/00
摘要： Cytokine CC-1 having the amino acid sequence according to SEQ ID No. 6 and its biologically active fragments and/or derivatives, in particular amidized, acetylized, phosphorylized and/or glycosylized derivatives.
摘要翻译： 具有根据SEQ ID No.6的氨基酸序列的细胞因子CC-1及其生物活性片段和/或衍生物，特别是酰胺化的，乙酰化的，磷酸化的和/或糖基化的衍生物。
-
公开(公告)号：US06809175B1
公开(公告)日：2004-10-26
申请号：US09509559
申请日：2000-11-27
申请人： Wolf-Georg Forssmann , Ludger Standker , Markus Meyer , Hossein Mostafavi , Hans-Georg Opitz , Lothar Kling
发明人： Wolf-Georg Forssmann , Ludger Standker , Markus Meyer , Hossein Mostafavi , Hans-Georg Opitz , Lothar Kling
IPC分类号： C07K1400
CPC分类号： C07K14/705 , A61K38/00 , C07K14/475
摘要： A peptide referred to as cadherin-derived growth factor (CDGF) the sequence of which corresponds to a partial sequence of a pre-pro-cadherin, said pre-pro-cadherin comprising the domains signal sequence, pro sequence cadherin repeats, transmembrane region and intracellular domain, characterized in that the sequence of said peptide comprises the pro sequence, that at least one of the other domains of the pre-pro-cadherin is lacking, and that said peptide has cell-proliferative, cell-protective and/or cell-differential properties.
摘要翻译： 称为钙粘蛋白衍生生长因子（CDGF）的肽，其序列对应于前前钙粘蛋白的部分序列，所述前前钙粘蛋白包含结构域信号序列，前序列钙粘着蛋白重复序列，跨膜区和 细胞内结构域，其特征在于所述肽的序列包含前序列，所述前体前钙粘蛋白的至少一个其他结构域缺乏，并且所述肽具有细胞增殖，细胞保护和/或细胞 差分属性。
-
公开(公告)号：US6083483A
公开(公告)日：2000-07-04
申请号：US272759
申请日：1999-03-19
申请人： Christian Stief , Torsten Strohmeyer , Wolf-Georg Forssmann , Markus Meyer , Peter Schulz-Knappe , Akmal Taher
发明人： Christian Stief , Torsten Strohmeyer , Wolf-Georg Forssmann , Markus Meyer , Peter Schulz-Knappe , Akmal Taher
IPC分类号： C07D239/96 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/415 , A61K31/4166 , A61K31/44 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/522 , A61K31/54 , A61K31/541 , A61K45/00 , A61P1/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/273 , C07D241/18 , C07D333/70 , C07D473/06 , A61K49/04 , A61B5/055
CPC分类号： A61K31/522 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/415 , A61K31/4166 , A61K31/44 , A61K31/50 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/54 , A61K31/541
摘要： The invention relates to the use of inhibitors of phosphodiesterase IV for the modulation of the motility and peristalsis of the hollow organs of the urogenital and gastrointestinal tract.
摘要翻译： 本发明涉及磷酸二酯酶IV抑制剂用于调节泌尿生殖道和胃肠道中空器官的运动和蠕动的用途。
-
公开(公告)号：US20110257099A1
公开(公告)日：2011-10-20
申请号：US12767395
申请日：2010-04-26
CPC分类号： A61K38/2242 , A61K47/26
摘要： The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
摘要翻译： 本发明涉及尿钠肽如尿d素用于治疗患有心力衰竭的患者，例如急性失代偿性心力衰竭。 优选地，将包含有效量的尿布菌素的组合物在至少24小时和至多120小时，优选至少48小时的持续时间内静脉内施用于患者。
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.038 秒)